{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:52:55Z","timestamp":1789008775575,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1714,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1111\/j.1600-0609.2010.01541.x","type":"journal-article","created":{"date-parts":[[2010,10,13]],"date-time":"2010-10-13T17:09:17Z","timestamp":1286989757000},"page":"124-128","source":"Crossref","is-referenced-by-count":63,"title":["Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*"],"prefix":"10.1111","volume":"86","author":[{"given":"Sari","family":"Riihij\u00e4rvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Taskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,22]]},"reference":[{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","author":"IPI-Project","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/10428190701809156","article-title":"Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab","volume":"49","author":"Ngo","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"3715a","DOI":"10.1182\/blood.V114.22.3715.3715","article-title":"Male sex is associated with lower rituximab trough serum levels and evolves as a significant prognostic factor in elderly patients with DLBCL treated with R-CHOP: results from 4 prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL)","volume":"114","author":"Pfreundschuh","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01541.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cancergencyto.2009.12.004","article-title":"Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma","volume":"198","author":"Cho","year":"2010","journal-title":"Cancer Genet Cytogenet"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01541.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2010.01541.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T06:09:25Z","timestamp":1625638165000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01541.x"}},"subtitle":["Gender-associated survival in B-cell lymphomas"],"short-title":[],"issued":{"date-parts":[[2010,12,22]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01541.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12,22]]}}}